Allergan posting of Restasis X study a positive, says Wells Fargo Wells Fargo notes that Allergan yesterday posted a new phase 2 study for Restasis X on clinicaltrials.gov which stated the trial will start in May 2014 and be completed in November 2016. Wells says Restasis X is a new formulation of Allergan's current dry eye drug, Restasis, and a potentially important part of the company's generic counter-strategy. The firm views the trial posting as an incremental positive for the company and keeps a Market Perform rating on Allergan.
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.